カテゴリ： MarketsandMarkets, 世界, 医療/バイオ

心臓安全サービスの世界市場予測（～2028）：種類別、サービス別、エンドユーザー別、地域別

■ 英語タイトル：Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter Measurement, Blood Pressure Measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical & Biopharma, CROs), Region - Global Forecast to 2028

調査会社MarketsandMarkets社が発行したリサーチレポート（データ管理コード：PH7455-23）■ 発行会社/調査会社：MarketsandMarkets
■ 商品コード：PH7455-23
■ 発行日：2023年10月17日
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：199
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥742,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥997,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,222,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[心臓安全サービスの世界市場予測（～2028）：種類別、サービス別、エンドユーザー別、地域別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

"世界の心臓安全サービス市場は、2023年の7億3900万米ドルから2028年には12億8200万米ドルに達すると予測され、2023年から2028年の予測期間中のCAGRは11.6%" この市場の成長は、心血管疾患の罹患率の上昇、研究開発活動の増加、心臓安全サービスのアウトソーシングの増加に起因しています。例えば、活発な医薬品パイプラインは、主に研究活動の増加によって毎年増加しています。製薬会社は競争力を維持し、中核機能に集中するため、研究活動を学術機関やCRO（医薬品開発業務受託機関）にアウトソーシングするケースが増えています。主にアウトソーシングされる研究開発業務は、基礎研究から後期開発、遺伝子工学、ターゲットバリデーション、アッセイ開発、ヒット探索・リード最適化（ヒット候補アズ・ア・サービス）、動物モデルでの安全性試験・テスト、ヒトを対象とした臨床試験まで多岐にわたります。製薬会社のパイプラインが拡大していることが、サービスのアウトソーシングが増加している主な理由です。

"予測期間中、製薬・バイオ製薬企業セグメントがエンドユーザー別で最大のシェアを占める"
2022年、世界の心臓安全サービス市場において、製薬・バイオ製薬企業セグメントがエンドユーザー別で最大のシェアを占めました。心臓安全サービスは、多様な病状や疾患に対する革新的な治療法の開発に専念する製薬・バイオ製薬企業によって、新開発薬の臨床試験を監督するために利用されています。これらの企業は、医薬品開発に関連する正確なデータを提供し、その後、規制当局に提出する申請書を完成させる必要があります。心臓の安全性に関する懸念は、潜在的に有望な医薬品の開発中止の原因となることが多いため、製薬・バイオ医薬品企業では心臓安全サービスに対する大きな需要が生じています。

"欧州は心臓安全サービス市場で2番目に大きい地域"
欧州は、心臓安全サービス市場において北米に次いで2番目に大きな市場を占めています。欧州の心臓安全サービス市場は、慢性疾患の罹患率の増加などの人口動態の変化により、近年著しい成長を遂げています。この背景には、同地域における老年人口の増加があります。欧州委員会の発表によると、2025年までにヨーロッパ人の20%以上が65歳以上になると予想されており、80歳以上の高齢者も急増することから、医療サービスに対する需要が大きく伸びることが予想されます。このことは、新薬発見のための製薬・バイオ医薬品の臨床試験活動を促進し、心臓安全サービスなどの関連市場の成長に直接貢献するでしょう。

本レポートのために実施した一次インタビューは以下のように分類されます。
- 回答者別 供給側70％、需要側30%
- 役職別 Cレベル50%、Dレベル20%、その他30%
- 地域別 北米35％、欧州24％、アジア太平洋地域25％、中南米10％、中東4％、アフリカ2%

レポート掲載企業一覧
• Laboratory Corporation of America Holdings (US)
• Medpace (US)
• Koninklijke Philips N.V. (Netherland)
• Clario (US)
• Ncardia (Netherlands)
• IQVIA (US)
• Certara (US)
• PPD Inc. (Part of Thermo Fisher Scientific, Inc.) (US)
• SGS S.A. (Switzerland)
• ICON Plc (Ireland)
• WuXi AppTec (China)
• Charles River Laboratories (US)
• Eurofins Scientific (Luxembourg)
• Frontage Labs (US)
• Banook Group (France)
• Biotrial (France)
• Celerion (US)
• Richmond Pharmacology (UK)
• PhysioStim (France)
• Shanghai Medicilon Inc. (China)
• ACM Global Laboratories (India)
• Worldwide Clinical Trials (US)
• Nova Research Laboratories LLC (US)
• Biobeat (Israel)
• CRS. Experts. Early Phase. (Germany)

調査対象範囲
この調査レポートは、心臓安全サービス市場を詳細に掲載しています。種類、サービスタイプ、エンドユーザー、地域などの異なるセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィールや最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競争状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、および課題に関する情報を提供することを可能にします。

本レポートは、以下のポイントに関する洞察を提供します：
- 市場の成長に影響を与える主要な促進要因（心血管疾患の罹患率の増加、心臓安全サービス関連業務のアウトソーシングの増加、心臓関連の問題に関連する臨床試験の多さ）、阻害要因（厳しい規制とコンプライアンスガイドライン、心毒性試験の不適切さ）、機会（心毒性を抑制する新しい方法の出現、バイオシミラーと生物製剤の成長）、課題（心臓安全性評価サービスの高コスト）の分析を行っています。
- サービスの開発/革新：新たに開始されたサービスプラットフォームに関する詳細な洞察と心臓安全サービス市場の技術評価を提供します。
- 市場開発：有利な市場に関する包括的な情報 - 当レポートでは様々な地域の市場を分析しています。
- 市場の多様化：心臓安全サービス市場における新サービス、未開拓地域、最近の開発、投資に関する詳細情報を提供します。
- 競合評価：Laboratory Corporation of America Holdings (US), Medpace (US), Koninklijke Philips N.V. (Netherland), Clario (US), Ncardia (Netherlands), IQVIA (US), Certara (US), PPD Inc. (Part of Thermo Fisher Scientific, Inc.) (US), SGS S.A. (Switzerland), ICON Plc (Ireland), WuXi AppTec (China), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), Frontage Labs (US), Banook Group (France), Biotrial (France), Celerion (US), Richmond Pharmacology (UK), PhysioStim (France), Shanghai Medicilon Inc. (China), ACM Global Laboratories (India), Worldwide Clinical Trials (US), Nova Research Laboratories LLC (US), Biobeat (Israel), and CRS. Experts. Early Phase. (Germany).などの企業情報が含まれています。

1 イントロダクション
2 調査方法
3 エグゼクティブサマリー
4 プレミアムインサイト
5 市場概要
6 心臓安全サービスの世界市場：タイプ別
7 心臓安全サービスの世界市場：サービスタイプ別
8 心臓安全サービスの世界市場：エンドユーザー別
9 心臓安全サービスの世界市場：地域別
10 競争状況
11 企業情報
12 付録

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS AND EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
FIGURE 1 CARDIAC SAFETY SERVICES MARKET SEGMENTATION 28
1.3.2 YEARS CONSIDERED 28
1.4 CURRENCY CONSIDERED 29
1.5 LIMITATIONS 29
1.6 STAKEHOLDERS 29
1.6.1 RECESSION IMPACT 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 2 RESEARCH DESIGN 31
2.1.1 SECONDARY DATA 32
2.1.2 PRIMARY DATA 33
FIGURE 3 CARDIAC SAFETY SERVICES MARKET: BREAKDOWN OF PRIMARIES 33
2.2 MARKET SIZE ESTIMATION 34
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 34
FIGURE 5 MARKET SIZE ESTIMATION FOR CARDIAC SAFETY SERVICES: REVENUE SHARE ANALYSIS 35
2.2.1 INSIGHTS FROM PRIMARIES 36
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 36
2.2.2 SEGMENTATION ASSESSMENT (BY TYPE, SERVICE TYPE, AND END USER) 36
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 36
2.3 GROWTH FORECAST 37
FIGURE 8 CARDIAC SAFETY SERVICES MARKET: CAGR PROJECTIONS 38
FIGURE 9 CARDIAC SAFETY SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 38
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 39
FIGURE 10 DATA TRIANGULATION METHODOLOGY 39
2.5 RESEARCH ASSUMPTIONS 40
2.6 RISK ANALYSIS 40
2.7 RECESSION IMPACT ANALYSIS 40
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 40
 
3 EXECUTIVE SUMMARY 42
FIGURE 11 CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 42
FIGURE 12 CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2023 VS. 2028 (USD MILLION) 43
FIGURE 13 CARDIAC SAFETY SERVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 43
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF CARDIAC SAFETY SERVICES MARKET 44
4 PREMIUM INSIGHTS 45
4.1 CARDIAC SAFETY SERVICES MARKET OVERVIEW 45
FIGURE 15 RISING INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 45
4.2 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE AND COUNTRY (2022) 46
FIGURE 16 INTEGRATED SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 46
4.3 CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2023 VS. 2028 46
FIGURE 17 ECG/HOLTER MEASUREMENT SERVICES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 46
4.4 CARDIAC SAFETY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
FIGURE 18 EUROPEAN COUNTRIES TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 49
FIGURE 19 CARDIAC SAFETY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES, AND TRENDS 49
TABLE 2 CARDIAC SAFETY SERVICES MARKET: IMPACT ANALYSIS 50
5.2.1 DRIVERS 50
5.2.1.1 Rising incidence of cardiovascular diseases 50
5.2.1.2 Increasing outsourcing of services to CROs 51
5.2.1.3 High number of clinical trials for cardiac treatments 52
FIGURE 20 TOTAL CLINICAL TRIAL REGISTRATIONS WORLDWIDE (2000−2022) 52
5.2.2 RESTRAINTS 53
5.2.2.1 Stringent regulations and compliance guidelines 53
5.2.2.2 Inadequacy of cardiotoxicity testing 54
5.2.3 OPPORTUNITIES 54
5.2.3.1 Emergence of innovative testing methods 54
5.2.3.2 Growth in biosimilars and biologics development 55
5.2.4 CHALLENGES 56
5.2.4.1 High cost of cardiac safety evaluation services 56
5.2.5 TRENDS 56
5.2.5.1 Rising technological advancements 56
5.2.5.2 Transition to patient-centric approach 57
5.3 TECHNOLOGY ANALYSIS 58
5.4 VALUE CHAIN ANALYSIS 59
FIGURE 21 CARDIAC SAFETY SERVICES MARKET: VALUE CHAIN ANALYSIS 59
5.5 ECOSYSTEM ANALYSIS 60
FIGURE 22 CARDIAC SAFETY SERVICES MARKET: ECOSYSTEM ANALYSIS 60
5.6 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 3 CARDIAC SAFETY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.6.1 INTENSITY OF COMPETITIVE RIVALRY 60
5.6.2 BARGAINING POWER OF SUPPLIERS 61
5.6.3 BARGAINING POWER OF BUYERS 61
5.6.4 THREAT OF SUBSTITUTES 61
5.6.5 THREAT OF NEW ENTRANTS 61
5.7 REGULATORY ANALYSIS 61
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
TABLE 4 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
TABLE 5 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 8 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
5.8 PRICING ANALYSIS 64
5.9 KEY CONFERENCES AND EVENTS 65
TABLE 9 CARDIAC SAFETY SERVICES MARKET: LIST OF KEY CONFERENCES AND EVENTS (2023–2024) 65
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 66
FIGURE 23 CARDIAC SAFETY SERVICES MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 66
5.10.2 BUYING CRITERIA 67
FIGURE 24 KEY BUYING CRITERIA FOR END USERS 67
6 CARDIAC SAFETY SERVICES MARKET, BY TYPE 68
6.1 INTRODUCTION 69
TABLE 10 CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 69
6.2 INTEGRATED SERVICES 69
6.2.1 COMPREHENSIVE DATA INTEGRATION AND IMPROVED QUALITY TO PROPEL MARKET 69
TABLE 11 INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 70
TABLE 12 NORTH AMERICA: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 70
TABLE 13 EUROPE: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 71
TABLE 14 ASIA PACIFIC: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 71
TABLE 15 LATIN AMERICA: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 72
6.3 STANDALONE SERVICES 72
6.3.1 COST-EFFECTIVE BENEFITS TO SUPPORT MARKET GROWTH 72
TABLE 16 STANDALONE CARDIAC SAFETY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 73
TABLE 17 NORTH AMERICA: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 18 EUROPE: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 74
TABLE 19 ASIA PACIFIC: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 74
TABLE 20 LATIN AMERICA: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 75
7 CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE 76
7.1 INTRODUCTION 77
TABLE 21 CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 77
7.2 ECG/HOLTER MEASUREMENT SERVICES 77
7.2.1 FEATURES SUCH AS TREND ASSESSMENT AND ENHANCED QUALITY METRICS TO BOOST DEMAND 77
TABLE 22 ECG/HOLTER MEASUREMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 78
TABLE 23 NORTH AMERICA: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 24 EUROPE: ECG/HOLTER MEASUREMENT SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 25 ASIA PACIFIC: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 26 LATIN AMERICA: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
7.3 BLOOD PRESSURE MEASUREMENT SERVICES 80
7.3.1 GROWING IMPORTANCE IN CARDIOVASCULAR HEALTH ASSESSMENT TO SUPPORT GROWTH 80
TABLE 27 BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 81
TABLE 28 NORTH AMERICA: BLOOD PRESSURE MANAGEMENT SERVICES MARKET BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 29 EUROPE: BLOOD PRESSURE MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 30 ASIA PACIFIC: BLOOD PRESSURE MANAGEMENT SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 31 LATIN AMERICA: BLOOD PRESSURE MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
7.4 CARDIOVASCULAR IMAGING SERVICES 83
7.4.1 NEED TO ASSESS DRUG EFFICACY AND SAFETY TO PROPEL DEMAND 83
TABLE 32 CARDIOVASCULAR IMAGING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 84
TABLE 33 NORTH AMERICA: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 34 EUROPE: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 35 ASIA PACIFIC: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 36 LATIN AMERICA: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
7.5 THOROUGH QT STUDIES 86
7.5.1 NEED TO CONDUCT CLINICAL INVESTIGATIONS AND MEASURE MEDICAL INTERVENTION TO DRIVE GROWTH 86
TABLE 37 THOROUGH QT STUDIES MARKET, BY REGION, 2021–2028 (USD MILLION) 87
TABLE 38 NORTH AMERICA: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 39 EUROPE: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 40 ASIA PACIFIC: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 41 LATIN AMERICA: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
7.6 OTHER CARDIAC SAFETY SERVICES 89
TABLE 42 OTHER CARDIAC SAFETY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 43 NORTH AMERICA: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 44 EUROPE: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 45 ASIA PACIFIC: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 46 LATIN AMERICA: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
8 CARDIAC SAFETY SERVICES MARKET, BY END USER 92
8.1 INTRODUCTION 93
TABLE 47 CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 93
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 93
8.2.1 GROWING COLLABORATIONS FOR CLINICAL TRIALS TO PROPEL MARKET 93
TABLE 48 CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 94
TABLE 49 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 50 EUROPE: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 51 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 52 LATIN AMERICA: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 96
8.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) 96
8.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES TO DRIVE MARKET 96
TABLE 53 CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2021–2028 (USD MILLION) 96
TABLE 54 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 55 EUROPE: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 56 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 57 LATIN AMERICA: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2021–2028 (USD MILLION) 98
9 CARDIAC SAFETY SERVICES MARKET, BY REGION 99
9.1 INTRODUCTION 100
TABLE 58 CARDIAC SAFETY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 100
9.2 NORTH AMERICA 100
FIGURE 25 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SNAPSHOT 101
TABLE 59 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 60 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 102
TABLE 61 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 103
TABLE 62 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.2.1 US 104
9.2.1.1 Increasing clinical trials for drug discovery & development to drive market 104
TABLE 63 TOTAL NUMBER OF CLINICAL TRIALS REGISTERED 104
TABLE 64 US: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 105
TABLE 65 US: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 105
TABLE 66 US: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 105
9.2.2 CANADA 106
9.2.2.1 Availability of high-end facilities for drug discovery to propel market 106
TABLE 67 CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 106
TABLE 68 CANADA: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 107
TABLE 69 CANADA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.2.3 NORTH AMERICA: RECESSION IMPACT 108
9.3 EUROPE 108
FIGURE 26 EUROPE: CARDIAC SAFETY SERVICES MARKET SNAPSHOT 109
TABLE 70 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 71 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 72 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 111
TABLE 73 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 111
9.3.1 GERMANY 111
9.3.1.1 High pharmaceutical production to propel market 111
TABLE 74 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 75 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 112
TABLE 76 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 113
9.3.2 UK 113
9.3.2.1 Growth in life science research to drive market 113
TABLE 77 UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 78 UK: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 114
TABLE 79 UK: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 114
9.3.3 FRANCE 114
9.3.3.1 Growing focus on biosimilars to fuel market 114
TABLE 80 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 81 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 115
TABLE 82 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 116
9.3.4 ITALY 116
9.3.4.1 Availability of funding for novel services to support market growth 116
TABLE 83 ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 116
TABLE 84 ITALY: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 117
TABLE 85 ITALY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 117
9.3.5 SPAIN 117
9.3.5.1 Presence of multinational pharma companies to drive market 117
TABLE 86 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 87 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 118
TABLE 88 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 119
9.3.6 REST OF EUROPE 119
TABLE 89 REST OF EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 90 REST OF EUROPE: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 120
TABLE 91 REST OF EUROPE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 121
9.3.7 EUROPE: RECESSION IMPACT 121
9.4 ASIA PACIFIC 121
TABLE 92 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 93 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 94 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 123
TABLE 95 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 123
9.4.1 CHINA 123
9.4.1.1 China to dominate APAC market for cardiac safety services 123
TABLE 96 CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 97 CHINA: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 124
TABLE 98 CHINA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 125
9.4.2 JAPAN 125
9.4.2.1 Supportive regulatory policies for safety measures to drive market 125
TABLE 99 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 100 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 126
TABLE 101 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 126
9.4.3 INDIA 126
9.4.3.1 Rising growth in pharmaceutical & biotechnology industries to propel market 126
TABLE 102 INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 103 INDIA: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 127
TABLE 104 INDIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 128
9.4.4 AUSTRALIA 128
9.4.4.1 Rising investments by medical device companies to support market growth 128
TABLE 105 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 106 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 129
TABLE 107 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 129
9.4.5 REST OF ASIA PACIFIC 129
TABLE 108 REST OF ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 109 REST OF ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 130
TABLE 110 REST OF ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 131
9.4.6 ASIA PACIFIC: RECESSION IMPACT 131
9.5 LATIN AMERICA 131
TABLE 111 LATIN AMERICA: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 112 LATIN AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 113 LATIN AMERICA: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 132
TABLE 114 LATIN AMERICA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 133
9.5.1 BRAZIL 133
9.5.1.1 Low costs and presence of skilled clinical investigators to drive market 133
TABLE 115 BRAZIL: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 116 BRAZIL: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 134
TABLE 117 BRAZIL: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 134
9.5.2 REST OF LATIN AMERICA 134
TABLE 118 REST OF LATIN AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 119 REST OF LATIN AMERICA: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 135
TABLE 120 REST OF LATIN AMERICA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 136
9.5.3 LATIN AMERICA: RECESSION IMPACT 136
9.6 MIDDLE EAST 136
9.6.1 GROWING CRO HUB TO DRIVE MARKET 136
TABLE 121 MIDDLE EAST: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 122 MIDDLE EAST: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 137
TABLE 123 MIDDLE EAST: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 138
9.6.2 MIDDLE EAST: RECESSION IMPACT 138
9.7 AFRICA 139
9.7.1 RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO SUPPORT MARKET GROWTH 139
TABLE 124 AFRICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 125 AFRICA: CARDIAC SAFETY SERVICES MARKET, BY SERVICE TYPE, 2021–2028 (USD MILLION) 140
TABLE 126 AFRICA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 140
9.7.2 AFRICA: RECESSION IMPACT 141
10 COMPETITIVE LANDSCAPE 142
10.1 INTRODUCTION 142
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 143
FIGURE 27 CARDIAC SAFETY SERVICES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS (2020−2023) 143
10.3 MARKET SHARE ANALYSIS 144
FIGURE 28 CARDIAC SAFETY SERVICES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 144
TABLE 127 CARDIAC SAFETY SERVICES MARKET: INTENSITY OF COMPETITIVE RIVALRY 144
10.4 REVENUE SHARE ANALYSIS 145
FIGURE 29 REVENUE SHARE ANALYSIS FOR KEY COMPANIES (2020−2022) 145
10.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 146
10.5.1 STARS 146
10.5.2 PERVASIVE PLAYERS 146
10.5.3 EMERGING LEADERS 146
10.5.4 PARTICIPANTS 147
FIGURE 30 CARDIAC SAFETY SERVICES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 147
 
10.6 COMPETITIVE BENCHMARKING OF LEADING 25 PLAYERS (2022) 148
10.6.1 SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES) 148
TABLE 128 CARDIAC SAFETY SERVICES MARKET: SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS 148
10.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 149
TABLE 129 CARDIAC SAFETY SERVICES MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 149
10.7 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES 150
10.7.1 PROGRESSIVE COMPANIES 150
10.7.2 RESPONSIVE COMPANIES 150
10.7.3 DYNAMIC COMPANIES 150
10.7.4 STARTING BLOCKS 150
FIGURE 31 CARDIAC SAFETY SERVICES MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 151
10.8 COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS (2022) 152
TABLE 130 CARDIAC SAFETY SERVICES MARKET: DETAILED LIST OF STARTUPS/SME PLAYERS 152
TABLE 131 CARDIAC SAFETY SERVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS 153
10.9 COMPETITIVE SCENARIO AND TRENDS 153
10.9.1 SERVICE LAUNCHES 153
TABLE 132 CARDIAC SAFETY SERVICES MARKET: SERVICE LAUNCHES (JANUARY 2020−SEPTEMBER 2023) 153
10.9.2 DEALS 154
TABLE 133 CARDIAC SAFETY SERVICES MARKET: DEALS (JANUARY 2020−SEPTEMBER 2023) 154
10.9.3 OTHER DEVELOPMENTS 155
TABLE 134 CARDIAC SAFETY SERVICES MARKET: OTHER DEVELOPMENTS (JANUARY 2020−SEPTEMBER 2023) 155
11 COMPANY PROFILES 157
11.1 KEY PLAYERS 157
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS 157
TABLE 135 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW 157
FIGURE 32 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022) 158
11.1.2 MEDPACE 160
TABLE 136 MEDPACE: BUSINESS OVERVIEW 160
FIGURE 33 MEDPACE: COMPANY SNAPSHOT (2022) 160
11.1.3 KONINKLIJKE PHILIPS N.V. 163
TABLE 137 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW 163
FIGURE 34 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 164
11.1.4 CLARIO 166
TABLE 138 CLARIO: BUSINESS OVERVIEW 166
11.1.5 NCARDIA 168
TABLE 139 NCARDIA: BUSINESS OVERVIEW 168
11.1.6 IQVIA 169
TABLE 140 IQVIA: BUSINESS OVERVIEW 169
FIGURE 35 IQVIA: COMPANY SNAPSHOT (2022) 170
11.1.7 CERTARA 171
TABLE 141 CERTARA: BUSINESS OVERVIEW 171
FIGURE 36 CERTARA: COMPANY SNAPSHOT (2022) 172
11.1.8 PPD, INC. (PART OF THERMO FISHER SCIENTIFIC, INC.) 173
TABLE 142 PPD, INC.: BUSINESS OVERVIEW 173
FIGURE 37 PPD, INC.: COMPANY SNAPSHOT (2022) 174
11.1.9 SGS S.A. 177
TABLE 143 SGS S.A.: BUSINESS OVERVIEW 177
FIGURE 38 SGS S.A.: COMPANY SNAPSHOT (2022) 178
11.1.10 ICON PLC 180
TABLE 144 ICON PLC: BUSINESS OVERVIEW 180
FIGURE 39 ICON PLC: COMPANY SNAPSHOT (2022) 180
11.1.11 WUXI APPTEC 182
TABLE 145 WUXI APPTEC: BUSINESS OVERVIEW 182
FIGURE 40 WUXI APPTEC: COMPANY SNAPSHOT (2022) 183
11.1.12 CHARLES RIVER LABORATORIES 184
TABLE 146 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 184
FIGURE 41 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 185
11.1.13 EUROFINS SCIENTIFIC 186
TABLE 147 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 186
FIGURE 42 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 186
11.1.14 FRONTAGE LABS 188
TABLE 148 FRONTAGE LABS: BUSINESS OVERVIEW 188
FIGURE 43 FRONTAGE LABS: COMPANY SNAPSHOT (2022) 189
11.1.15 BANOOK GROUP 191
TABLE 149 BANOOK GROUP: BUSINESS OVERVIEW 191
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS 193
11.2.1 BIOTRIAL 193
11.2.2 CELERION 193
11.2.3 RICHMOND PHARMACOLOGY 194
11.2.4 PHYSIOSTIM 194
11.2.5 SHANGHAI MEDICILON INC. 195
11.2.6 ACM GLOBAL LABORATORIES 195
11.2.7 WORLDWIDE CLINICAL TRIALS 196
11.2.8 NOVA RESEARCH LABORATORIES LLC 196
11.2.9 BIOBEAT 197
11.2.10 CRS. EXPERTS. EARLY PHASE. 197
12 APPENDIX 198
12.1 DISCUSSION GUIDE 198
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 202
12.3 CUSTOMIZATION OPTIONS 204
12.4 RELATED REPORTS 204
12.5 AUTHOR DETAILS 205



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 細胞ベースアッセイの世界市場予測（～2028）：製品＆サービス別、用途別、エンドユーザー別、地域別
  • カスタム抗体の世界市場予測（～2028）：サービス別、種類別、ソース別、用途別、疾患別、エンドユーザー別
  • 臨床試験用品の世界市場予測（～2028）：サービス別、フェーズ別、種類別、治療領域別、エンドユーザー別、地域別
  • 歯科用3Dプリントの世界市場予測（～2028）：製品＆サービス別、技術別、用途別、エンドユーザー別
  • 医療機器コネクティビティの世界市場予測（～2028）：製品・サービス別、技術別、用途別、エンドユーザー別、地域別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(PH7455-23 )"心臓安全サービスの世界市場予測（～2028）：種類別、サービス別、エンドユーザー別、地域別" (英文：Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter Measurement, Blood Pressure Measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical & Biopharma, CROs), Region - Global Forecast to 2028)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。